Drug Profile

BHV 1310

Alternative Names: BHV-1310

Latest Information Update: 12 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biohaven Pharmaceuticals
Class Small molecules
Mechanism of Action Immunoglobulin G degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Myasthenia gravis

Most Recent Events

05 Apr 2025 Pharmacodynamics data from preclinical studies in Myasthenia gravis presented at 77^th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
16 Dec 2024 IND application approved for BHV 1310 in Myasthenia gravis
16 Dec 2024 Biohaven plans a phase I trial for Myasthenia gravis in first quarter of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com